ID: MRFR/Pharma/5373-HCR | February 2021 | Region: Global | 90 pages
Market Scenario:
Global tinea corporis market is expected to rise steadily at a CAGR of 7.2% during forecast period of 2018-2023.
Tinea corporis is a fungal infection that is caused by tinea rubrum, trichophyton mentagrophytes and epidermophyton floccosum fungi. This fungal infection mainly occurs in humid climatic condition. It is also known as ringworm infection. Tinea corporis infection occurs mostly on arms, legs or can also occur on different parts of body. Tinea corporis is contagious infection which can spread from one person to other hence it is important not to share towel, flannels, bathmats with another person.
The global tinea corporis market is expected to see the growth in upcoming year due to entry of new drug product in market for treatment. Many key players in market are engaged in development of new drug product for tinea corporis treatment. The prevalence of tinea infection is higher in humid climatic condition. Increasing incidences of fungal diseases and increasing prevalence of various skin disorders are some of the key factors responsible for the market growth. Various other factors such as increasing awareness regarding skin infection, new drug development, are also driving the global tinea corporis market.
However certain factors that can hamper the growth of this market in near future are lack of awareness regarding fungal disease, adverse side effect due to antifungal drugs and alternative treatment plans.
Key players:
Some of the key players in the global tinea corporis market are Taro Pharmaceuticals., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc, Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Limited, and Camber Pharmaceuticals, Inc., AvKare, Inc., Novartis AG, Sebela Pharmaceuticals, Inc., Bayer AG, Blueberry Therapeutics Ltd, Perrigo Company.
Intended Audience
Market Segmentation:
Global tinea corporis market is segmented into drug type, diagnosis, treatment and end-users. Tinea corporis market on basis of drug types is segmented into antifungals, steroids and anti-infective combinations.
Based on diagnosis tinea corporis market is segmented into physical exam, imaging tests. Imaging test is further sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy and others.
Based on treatment tinea corporis market is segmented into antifungal shampoos, antifungal creams, drugs and others. On basis of end-user market is further segmented into hospital pharmacies, drug stores, online pharmacies, dermatology hospitals, medical research centres, academic institutes others.\
Global Tinea Corporis Market by Drug Type
Global Tinea Corporis Market, by Diagnosis
Global Tinea Corporis Market, by Treatment
Global Tinea Corporis Market, by End-Users
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The tinea corporis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of the tinea corporis market.
The European tinea corporis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The tinea corporis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The tinea corporis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Tinea Corporis Market Share (%), by Region, 2017
Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon
Regional Market Summary
Geographically, the America holds the highest market share for tinea corporis market and the reason being many market players are engaged in development of new drug product innovation, and as this infection is more prone to humid climatic condition there is an increasing prevalence of fungal infection in this region. Whereas increasing awareness of fungal disease and rising healthcare expenditure by the government are some of the factors responsible for growth of market in this region
Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of fungal infection, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region.
Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of fungal infection, changing lifestyle, increase in population, increasing healthcare expenditure by government are some of the factor responsible for market growth in this region.
Global Tinea Corporis Market, by Region
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Tinea Corporis Market, by Drug Type
6.1 Introduction
6.2 Antifungals
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
6.3 Steroids
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
6.4 Anti-Infective Combinations
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
Chapter 7. Global Tinea Corporis Market, by Diagnosis
7.1 Introduction
7.2 Physical Exam
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.3 Imaging Tests
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.3.1 Wood Lamp (Black Light) Examination
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.3.2 Microscopy Using Potassium Hydroxide (KOH)
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.3.3 Fungal Culture
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.3.4 Skin Biopsy
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.3.5 Others
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
Chapter 8. Global Tinea Corporis Market, by Treatmant
8.1 Introduction
8.2 Antifungal Shampoos
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
8.3 Antifungal Creams
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
8.4 Drugs
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
8.5 Others
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
Chapter 9. Global Tinea Corporis Market, by End-Users
9.1 Introduction
9.2 Hospital Pharmacies
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
9.3 Drug Stores
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
9.4 Online Pharmacies
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
9.5 Dermatology hospitals
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
9.6 Others
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
Chapter 10. Global Tinea Corporis Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
Chapter 12. Company Profiles
12.1 Astellas Pharma
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Bayer AG
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Enzon Pharmaceuticals, Inc
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Galderma S.A.
12.4.1 Company Overview
12.4.2 Product Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Gilead
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Novartis AG
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Pfizer Inc
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financial Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.12 Taro Pharmaceutical Industries Ltd
12.12.1 Overview
12.12.2 Product Overview
12.12.3 Financials
12.12.4 Key Developments
12.12.5 SWOT Analysis
12.7 Teva Pharmaceutical Industries Ltd
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.12 Valeant
12.12.1 Overview
12.12.2 Product Overview
12.12.3 Financials
12.12.4 Key Developments
12.12.5 SWOT Analysis
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Predictions for the Tinea Corporis Market
Chapter 14. Appendix
LIST OF TABLES
Table 1 Global Tinea Corporis Market Synopsis, 2018–2023
Table 2 Global Tinea Corporis Market Estimates and Forecast, 2018–2023 (USD Million)
Table 3 Global Tinea Corporis Market, by Region, 2018–2023 (USD Million)
Table 4 Global Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 5 Global Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 6 Global Tinea Corporis Market, by Treatmant, 2018–2023 (USD Million)
Table 7 Global Tinea Corporis Market, by End-Users, 2018–2023 (USD Million0
Table 8 North America: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 9 North America: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 10 North America: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 11 North America: Tinea Corporis Market, by End-Users , 2018–2023 (USD Million)
Table 12 US: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 13 US: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 14 US: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 15 US: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)
Table 16 Canada: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 17 Canada: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 18 Canada: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 19 Canada: Tinea Corporis Market, by End-Users, 2018–2023 (USD Million)
Table 20 South America: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 21 South America: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 22 South America: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 23 South America: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)
Table 24 Europe: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 25 Europe: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 26 Europe: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 27 Europe: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)
Table 28 Western Europe: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 29 Western Europe: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 30 Western Europe: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 31 Western Europe: Tinea Corporis Market, by End-Users, 2018–2023 (USD Million)
Table 32 Eastern Europe: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 33 Eastern Europe: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 34 Eastern Europe: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 35 Eastern Europe: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)
Table 36 Asia-Pacific: Tinea Corporis Market, by Drug Type, 2018–2023 (USD Million)
Table 37 Asia-Pacific: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 38 Asia-Pacific: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 39 Asia-Pacific: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)
Table 40 Middle East & Africa: Tinea Corporis Market, by Drug Type, 20132-2023 (USD Million)
Table 41 Middle East & Africa: Tinea Corporis Market, by Diagnosis, 2018–2023 (USD Million)
Table 42 Middle East & Africa: Tinea Corporis Market, by Treatment, 2018–2023 (USD Million)
Table 43 Middle East & Africa: Tinea Corporis Market, by End-Usesr, 2018–2023 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Tinea Corporis Market
Figure 3 Segmentation Market Dynamics for Global Tinea Corporis Market
Figure 4 Global Tinea Corporis Market Share, by Drug Type, 2017
Figure 5 Global Tinea Corporis Market Share, by Diagnosis, 2017
Figure 6 Global Tinea Corporis Market Share, by Treatment, 2017
Figure 7 Global Tinea Corporis Market Share, by End-Users, 2017
Figure 8 Global Tinea Corporis Market Share, by Region, 2017
Figure 9 North America: Tinea Corporis Market Share, by Country, 2017
Figure 10 Europe: Tinea Corporis Market Share, by Country, 2017
Figure 11 Asia-Pacific: Tinea Corporis Market Share, by Country, 2017
Figure 12 Middle East & Africa: Tinea Corporis Market Share, by Country, 2017
Figure 13 Global Tinea Corporis Market: Company Share Analysis, 2017 (%)
Figure 14 Astellas Pharma: Key Financials
Figure 15 Astellas Pharma: Segmental Revenue
Figure 16 Astellas Pharma: Geographical Revenue
Figure 17 Bayer AG : Key Financials
Figure 18 Bayer AG : Segmental Revenue
Figure 19 Bayer AG : Geographical Revenue
Figure 20 Enzon Pharmaceuticals, Inc: Key Financials
Figure 21 Enzon Pharmaceuticals, Inc: Segmental Revenue
Figure 22 Enzon Pharmaceuticals, Inc: Geographical Revenue
Figure 23 Galderma S.A. : Key Financials
Figure 24 Galderma S.A. : Segmental Revenue
Figure 25 Galderma S.A. : Geographical Revenue
Figure 26 Gilead : Key Financials
Figure 27 Gilead : Segmental Revenue
Figure 28 Gilead . Geographical Revenue
Figure 29 Novartis AG : Key Financials
Figure 30 Novartis AG : Segmental Revenue
Figure 31 Novartis AG : Geographical Revenue
Figure 32 Pfizer Inc: Key Financials
Figure 33 Pfizer Inc: Segmental Revenue
Figure 34 Pfizer Inc: Geographical Revenue
Figure 35 Taro Pharmaceutical Industries Ltd: Key Financials
Figure 36 Taro Pharmaceutical Industries Ltd: Segmental Revenue
Figure 37 Taro Pharmaceutical Industries Ltd: Geographical Revenue
Figure 38 Teva Pharmaceutical Industries Ltd: Key Financials
Figure 39 Teva Pharmaceutical Industries Ltd: Segmental Revenue
Figure 40 Teva Pharmaceutical Industries Ltd: Geographical Revenue
Figure 41 Valeant : Key Financials
Figure 42 Valeant : Segmental Revenue
Figure 43 Valeant : Geographical Revenue